- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.08. | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 09.07. | Ernexa regains Nasdaq compliance, continues trading on exchange | 2 | Investing.com | ||
| 09.07. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements | 230 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
| 07.07. | Biotech-Unternehmen Ernexa Therapeutics beauftragt Haskell & White als neuen Wirtschaftsprüfer | 1 | Investing.com Deutsch | ||
| 07.07. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development | 2 | GlobeNewswire (USA) | ||
| 24.06. | Ernexa Therapeutics completes second closing of securities offering | 1 | Investing.com | ||
| 24.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement | 1 | GlobeNewswire (USA) | ||
| 12.06. | Ernexa Therapeutics kündigt Aktienzusammenlegung im Verhältnis 1:15 an | 3 | Investing.com Deutsch | ||
| 11.06. | Ernexa Therapeutics registers 57M shares for resale | 2 | Seeking Alpha | ||
| 11.06. | Ernexa Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 10.06. | Ernexa Announces 1-for-15 Reverse Stock Split Effective June 12 To Regain Nasdaq Compliance | - | RTTNews | ||
| 10.06. | Ernexa Therapeutics announces 1-for-15 reverse stock split | 1 | Investing.com | ||
| 10.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split | 226 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
| 09.06. | Ernexa Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 | 2 | GlobeNewswire (USA) | ||
| 14.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations | 142 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
| 08.05. | D.Boral Capital: Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference | 267 | Newsfile | Cambridge, Massachusetts--(Newsfile Corp. - May 8, 2025) - Ernexa Therapeutics (NASDAQ: ERNA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May... ► Artikel lesen | |
| 07.05. | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
| BIOXXMED | 0,450 | 0,00 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| OCUGEN | 0,883 | +1,94 % | Ocugen - Novel cell therapies for retinal diseases | Ocugen's modifier gene therapy (MGT) platform is designed to regulate gene expression to restore visual function across both genetically diverse inherited retinal diseases (IRDs) and retinal conditions... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| BIO-GATE | 0,940 | -4,08 % | EQS-Adhoc: Bio-Gate AG: Bio-Gate AG beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | EQS-Ad-hoc: Bio-Gate AG / Schlagwort(e): Kapitalmaßnahme/Sonstiges
Bio-Gate AG: Bio-Gate AG beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts
19.08.2025... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,452 | +18,95 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Debenture Units Financing | Montreal, Quebec--(Newsfile Corp. - August 22, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
| VAXART | 0,261 | -10,17 % | Vaxart veröffentlicht Mitschrift von Aktionärsgespräch nach starkem Kursverfall | ||
| BURCON NUTRASCIENCE | 1,600 | +5,96 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2026 First Quarter Results | Vancouver, British Columbia--(Newsfile Corp. - August 13, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,880 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| IMMUNIC | 0,760 | -6,06 % | EQS-News: Immunic AG: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Quarter Results
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
07.08.2025 / 12:30 CET/CEST
The... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Release of the Next CEO Corner Segment | ||
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| CEL-SCI | 10,720 | +12,37 % | CEL-SCI Corporation: CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer | Strong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East and North Africa market Patient access and reimbursement/sale in... ► Artikel lesen |
ERNEXA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,430 Euro und damit -6,54 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERNEXA THERAPEUTICS INC finden Sie auf Wallstreet Online.